NCT06508021: An ongoing trial by Ashibio Inc
This trial is ongoing. It must report results 4 years, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06508021 |
|---|---|
| Title | A Phase 2/3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study With Open-Label Extension (OLE) to Assess the Efficacy and Safety of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 25, 2024 |
| Completion date | Feb. 4, 2029 |
| Required reporting date | Feb. 4, 2030, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |